Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) EBT (2019 - 2025)

Historic EBT for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to -$9.1 million.

  • Biodesix's EBT rose 1417.42% to -$9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$40.0 million, marking a year-over-year increase of 824.26%. This contributed to the annual value of -$42.8 million for FY2024, which is 1596.37% up from last year.
  • Latest data reveals that Biodesix reported EBT of -$9.1 million as of Q3 2025, which was up 1417.42% from -$11.6 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's EBT ranged from a high of -$6.2 million in Q1 2021 and a low of -$18.8 million during Q1 2023
  • Moreover, its 5-year median value for EBT was -$11.6 million (2025), whereas its average is -$12.1 million.
  • In the last 5 years, Biodesix's EBT crashed by 29234.66% in 2021 and then surged by 4404.5% in 2023.
  • Quarter analysis of 5 years shows Biodesix's EBT stood at -$13.2 million in 2021, then decreased by 24.78% to -$16.4 million in 2022, then skyrocketed by 44.05% to -$9.2 million in 2023, then rose by 8.67% to -$8.4 million in 2024, then dropped by 8.62% to -$9.1 million in 2025.
  • Its EBT was -$9.1 million in Q3 2025, compared to -$11.6 million in Q2 2025 and -$10.8 million in Q1 2025.